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munocytochemisto, in the rat central nervous system. PEPTIDES 3(6) 941-954, 1982.--The distribution ofdynorphin in the 
central nervous system was investigated in rats pretreated with relatively high doses (3(10--400/zg) of colchicine administered 
intracerebroventricularly. To circumvent the problems of antibody cross-reactivity, antisera were generated against differ- 
ent portions as well as the full dynorphin molecule (i.e., residues 1-13, 7-17, or 1-17). For comparison, antisera to 
[Leu]enkephalin (residues 1-5) were also utilized. Dynorphin was found to be widely distributed throughout the neuraxis. 
lmmunoreactive neuronal perikarya exist in hypothalamic magnoceUular nuclei, periaqueductal gray, scattered reticular 
formation sites, and other brain stem nuclei, as well as in spinal cord. Additionally, dynorphin-positive fibers or terminals 
occur in the cerebral cortex, olfactory bulb, nucleus accumbens, caudate-putamen, globus pallidus, hypothalamus, sub- 
stantia nigra, periaqueductal gray, many brain stem sties, and the spinal cord. In many areas studied, dynorphin and 
enkephalin appeared to form parallel but probably separate anatomical systems. The results suggest that dynorphin occurs 
in neuronal systems that are immunocytochemically distinct from those containing other opioid peptides. 
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DYNORPHIN is an opioid peptide originally extracted and 
purified from porcine pituitary [24]. The incomplete se- 
quence, dynorphin-(1-13), contains [Leu]enkephalin at 
residues 1-5 at the NH2-terminus, but is much more potent in 
the guinea pig ileum myenteric plexus-longitudinal muscle 
bioassay. The entire amino acid sequence of the hep- 
tadecapeptide dynorphin is now known [22,69]. This se- 
quence is not found in the beta-endorphin precursor,  pro- 
opiomelanocortin [48] or the enkephalin precursor [11, 26, 
50], indicating that dynorphin arises from a separate 
biosynthetic route. The biosynthetic source of  dynorphin is 
the recently sequenced beta-neo-endorphin/dynorphin pre- 
cursor [35]. The anatomical distribution of dynorphin also 
differs from that of  beta-endorphin and the enkephalins. 
Radioimmunoassay studies reveal a wide distribution of im- 
munoreactive dynorphin in brain, with highest levels in hy- 
pothalamus, followed in descending order by pons-medulla 
and midbrain, hippocampus, striatum, cerebral cortex and 
cerebellum [23]. Immunohistochemical studies of dynorphin 
have shown its localization to be different from beta- 
endorphin [78]. Dynorphin immunoreactivity was localized 
in posterior pituitary and the magnocellular (supraoptic and 
paraventricular) nuclei of  the hypothalamus. Dynorphin- 
positive magnocellular perikarya were also found to contain 
vasopressin immunoreactivity and could be distinguished 
anatomically from enkephalin-positive parvocellular peri- 
karya in the paraventricular nucleus [77]. Thus, opioid pep- 
tide precursor and immunohistochemical studies independ- 
ently provide clear evidence for the separateness of beta- 
endorphin, enkephalin and dynorphin systems in brain. 
Although immunocytochemical studies have provided de- 
tailed information on the localization in brain of  beta- 
endorphin [5, 6, 7, 17, 49, 66, 75, 79, 80, 82, 83, 89] and the 
enkephalins [15, 18, 29, 30, 31, 34, 45, 55, 60, 62, 64, 71, 72, 
74, 81"], such studies of dynorphin distribution have not 
clearly revealed immunoreactivity in regions shown to have 
material detected by radioimmunoassay [23, 32, 47]. We 
have found that intracerebroventricular pretreatment of rats 
with very high doses of  colchicine permits the visualization 
of previously undetected immunoreactive enkephalin sys- 
tems in rat brain (Khachaturian et al., J. Neurosci., in press). In 
the present study, such colchicine pretreatments enabled the 
visualization of widespread extrahypothalamic systems of 
immunoreactive dynorphin neurons which in many cases 
have a parallel distribution with the enkephalins. Using 
antisera to various segments (i.e., 1-13, 7-17) or the full 
dynorphin molecule, we have been able to distinguish be- 
tween dynorphin-like immunoreactivity and enkephalin-like 
immunoreactivity in the brain and spinal cord. The prelimi- 
nary results of our findings have been reported elsewhere 
[84]. The focus of this paper, however,  will be on dynorphin 
distribution in the central nervous system with some era- 
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TABLE 1 
LIST OF ANTISERA 
Antibody Source Specificity Key Cross Reactivities 
Dynorphin: 1 - 1 7  Goldstein COOH-terminus No known peptides 
1 -13  Goldstein Dynorphin-(6-13) No known peptides 
7-17 Watson and COOH-terminus No known peptides 
Akil 
[Leu]enkephalin Watson and COOH-terminus <6% with [Met] 
(affmity purified) Akil enkephalin 
Serotonin Watson and No other known 
Akil indolamine or 
catecholamine 
Tyrosine T. Joh Not tested 
Hydroxylase 
phasis on its separateness from the enkephalins in selected 
brain regions. 
METHOD 
Adult, male Sprague-Dawley rats were treated with vary- 
ing amounts of colchicine (50-400/zg in 10/zl 0.9% NaCI) 
injected stereotaxically into the right lateral ventricle 
(Khachaturian et al., J. Neurosci., in press). After 24 or 48 
hours, each rat was anesthetized with sodium pentobarbital 
and perfused through the aorta with 50 ml of ice cold 0.9% 
saline followed by ice cold 0.1 M phosphate-buffered 4% for- 
maldehyde (pH 7.4) at 140 mm Hg for 30 minutes. The brains 
were removed, blocked, stored overnight in phosphate- 
buffered 15% sucrose at 4°C, and then frozen in isopentane at 
-40°C. Frontal and parasagittal sections of 20/xm thickness 
were cut in a cryostat  at -20°C, thaw-mounted onto subbed 
slides, and stored at -70°C. 
For  peroxidase-antiperoxidase immunocytochemistry 
[83], the tissues were air-dried and then incubated at 37°C 
with normal goat serum (GIBCO) at 1/30 dilution for 5-10 
minutes. Primary rabbit antisera to specific peptides (Table 
1) were diluted with 0.02 M phosphate-buffered saline (PBS) 
and 0.3% Triton X-100 and incubated for 1 hour at 37°C, and 
overnight at 4°C (approximately 24 hours). To ensure 
antibody specificity, some sections were incubated with 
antisera preadsorbed with excess peptide (25-50/~M) against 
which the antiserum was raised, as well as preadsorbed with 
other peptides with amino acid sequences in common with 
the original peptide (eg., dynorphin antiserum preadsorbed 
with [Leu]enkephalin). The next day, the sections were 
washed in PBS (3x 10 minutes), incubated for 5-10 minutes 
at 37°C with normal goat serum, and then with goat anti- 
rabbit serum (Sternberger-Meyer) at 1/100 dilution for 30 
minutes, and at 4°C overnight. On the third day, the tissues 
were washed in PBS, incubated for 5-10 minutes at 37°C 
with normal goat serum followed by anti-horseradish peroxi- 
dase (anti-HRP) serum at 1/200 dilution for 40 minutes, 
washed in PBS, and incubated with 4 p,g/ml HRP enzyme 
(Sigma, Type VI),for 40 minutes. To initiate the peroxidase 
reaction, the slide-mounted sections were immersed in a 
solution of 0.03% H20~ and 0.125 mg/ml diaminobenzidine 
(Sigma) for 15 minutes with constant stirring. The reacted 
sections were washed (3×10 minutes) in distilled water. 
briefly osmicated (2% OsO4), washed, dyhydrated and 
mounted with Permount. Observations and photography 
were performed utilizing a Leitz Orthoplan microscope. 
Several antisera to various portions of the dynorphin 
molecule were used in this study (Table 1). Dynorphin-(1-13) 
and dynorphin-17 were purchased from Peninsula Laborato- 
ries (San Carlos, CA) and dynorphin-(7-17) was synthesized 
in our laboratories. For comparative purposes we also em- 
ployed antisera generated against [Leu]enkephalin, seroto- 
nin and tyrosine hydroxylase (from Dr. T. Joh, Cornell Uni- 
versity). Certain antisera were purified using an affinity 
chromatography column with the peptide covalently linked 
to cyanogen bromide-activated Sepharose-4B [44]. This 
purification process increases the concentration of specific 
IgG molecules, resulting in an improved signal against a re- 
duced background [76]. 
RESULTS 
Dynorphin immunoreactivity is localized to perikarya and 
processes of neurons in many regions of  the central nervous 
system (see Fig. 1). We have noted dynorphin- 
immunoreactive perikarya in telencephalic structures such 
as the cerebral cortex, hippocampus and amygdala, in 
hypothalamic magnocellular neurons, in mesencephalic 
periaqueductal central gray and reticular formation, in pon- 
tine and medullary reticular neurons including certain sen- 
sory and motor nuclei, and also in the spinal cord. We have 
also observed dynorphin-immunoreactive processes and 
terminals in all the above areas and additionally in the olfac- 
tory bulb, nucleus accumbens, caudate-putamen, globus 
pallidus, preoptic area, hippocampal mossy fibers, substan- 
tia nigra, many areas of  the reticular formation including 
certain monoamine-containing nuclei, as well as in the spinal 
cord. The immunoreactive signal obtained using antisera 
against either dynorphin-(1-13) or dynorphin-17 (Fig. 4A, B, 
and C, D) was blocked by both of these peptides but not by 
[Leu]enkephalin, [Met]enkephalin, enkephalin-Arga-Gly 7- 
Leu 8, enkephalin-ArgS-Phe r, BAM-22P, peptide E, dynor- 
phin-B, t~-neo-endorphin, or/3-endorphin. 
In the telencephalon, dynorphin-positive terminals are lo- 
calized to some but not all olfactory bulb glomeruli (Fig. 2A). 
Here, immunoreactive fibers appear to originate in the olfac- 
tory nerve and innervate specific giomeruli. We have so far 
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FIG. I. A schematic summary of dynorphin distribution in the rat central nervous system, shown in 
parasagittal view (see text for details). Neuronal perikarya are represented by solid triangles, while 
fibers and terminals are shown as dots. 
been unable to detect dynorphin-positive perikarya in the 
olfactory bulb or nerve. Diffuse, as well as punctate, 
dynorphin-like immunoreactivity is seen in the nucleus ac- 
cumbens, caudate-putamen, globus pallidus, and preoptic 
area. Several regions of the cerebral cortex exhibit 
dynorphin-positive axonal processes including the frontal 
(Fig. 2B), parietal, cingulate, piriform, and entorhinal corti- 
cal areas. These fibers were frequently seen to traverse cor- 
tical layers I, II and III. Varicose immunoreactive processes 
were also noted in the lateral septum. In the amygdala, the 
central nucleus contains scattered small dynorphin-positive 
perikarya and fine varicose fibers (Fig. 3A). We have also 
noted scattered varicose fibers in the medial, lateral, cortical 
and basal amygdaloid nuclei. In the entorhinal cortex, a few 
small immunoreactive perikarya are distributed in layer II 
with distinct apical dendrites situated toward the surface and 
fine slender axons coursing into deeper layers (Fig 3B). Thus 
far, we have been able to detect only a few immunoreactive 
fibers in the perforant path linking the entorhinal cortex to 
the dentate gyrus. Within the hippocampal formation, a few 
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FIG. 2. Telencephalic dynorphin. Panel A shows punctate terminal 
immunoreactlvity in 3 olfactory bulb glomeruli (G). The center 
glomerulus appears to connect (arrows) with the olfactory nerve to 
the right which also contains immunoreactivity and may be the 
source of glomerular terminals. In Panel B, an immunoreactive fiber 
(arrows) is seen in lamina I of frontal cortex. Bars: 50/xm. 
small faintly immunoreactive dynorphin perikarya can be 
localized to the granule cell layer of the dentate gyrus. Also, 
in the dentate gyms, dense fiber immunoreactivity is seen in 
the hilar region which gives rise to mossy fibers that project 
to hippocampal fields CA3 and CA2 (Fig. 3 C,D). No im- 
munoreactivity was detected within field CAl .  
In the diencephalon, the most prominent dynorphin-like 
immunoreactivity is situated within the hypothalamus in the 
supraoptic, paraventricular and other accessory magnocellu- 
lar nuclei. In the supraoptic nucleus, many perikarya are 
dynorphin-immunoreactive (Fig. 4A), and further, their dis- 
tribution corresponds to that of the vasopressin-containing 
neurons [77]. In the paraventricular nucleus, dynorphin- 
positive perikarya are distributed within the lateral subnu- 
cleus which is also vasopressin-rich. Other immunoreactive 
neurons are seen throughout hypothalamus, especially in its 
dorsolateral aspects (Fig. 4C). No parvocellular paraven- 
tricular perikarya are immunoreactive, although parvocellu- 
lar dynorphin-positive perikarya exist in the arcuate nucleus. 
Immunoreactive dynorphin fibers are distributed in the 
above hypothalamic areas which contain positive perikarya. 
In the mesencephalon, diffuse dynorphin immunoreac- 
tivity can be seen in the substantia nigra pars reticulata. 
Small dynorphin-positive perikarya are scattered dorsally 
and laterally in the mesencephalic reticular formation. Some 
of these perikarya are localized within the lateral tegmental 
nucleus. In the periaqueductal gray, dynorphin-positive per- 
ikarya are seen to be localized ventrally and laterally (Fig. 
5A). These perikarya form a band continuous with other 
mesencephalic reticular perikarya described above. The 
position of the perikarya within the periaqueductal gray is 
somewhat different from the position of [Leu]enkephalin- 
containing perikarya, many of which appear to be situated 
more dorsally in this region (Fig. 5B). Furthermore, both 
dynorphin-positive and [Leu]enkephalin-positive neuronal 
populations exist outside the serotonergic nucleus raphe 
dorsalis (Fig. 5C). Some immunoreactive varicosities are 
also seen in the colliculi. 
In the pons, dynorphin-containing perikarya and fibers 
are seen scattered throughout the reticular formation. Par- 
ticular areas of density include the parabrachial nuclei (Fig. 
6A), where immunoreactive perikarya appear to form a 
group separate from that containing [Leu]enkephalin- 
positive perikarya (Fig. 6B). A few scattered perikarya and 
fibers are situated adjacent to the nucleus locus coeruleus 
and in the mesencephalic nucleus of the trigeminal nerve 
(Fig. 6A). Within locus coeruleus, only occasional positive 
varicosities are encountered. Dynorphin-immunoreactive fi- 
bers are also seen in the main sensory nucleus of  the trigemi- 
nai nerve, and the nucleus of the spinal tract as well as the 
spinal tract of the trigeminal nerve. More ventrally, positive 
varicosities can also be localized to the motor nucleus of the 
facial nerve. 
In the medulla, as in the pons, many small positive 
dynorphin-containing perikarya and varicosities are scat- 
tered within the reticular formation. Laterally, dynorphin- 
positive varicosities and occasional small perikarya are seen 
within the nucleus of the spinal tract of the trigeminal nerve. 
Within the nucleus raphe magnus, a few beaded varicosities 
could be detected. Many scattered immunoreactive peri- 
karya and fibers are seen in the noradrenergic nucleus A5 at 
the level of the superior olivary nucleus (Fig. 7C). More 
dorsally, immunoreactive fibers can be localized to the me- 
dial and spinal vestibular nuclei, as well as dorsal and ventral 
cochlear nuclei. In the caudal medulla, diffuse immunoreac- 
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FIG. 3. Telencephalic dynorphin. Panel A depicts immunoreactive perikarya and fibers in the central amygdaloid nucleus. 
Panel B shows an immunoreactive neuron in lamina II of the entorhinai cortex. Note the slender axon (arrow) and the apical 
dendrite (arrow-head) directed toward the cortical surface. Hippocampal mossy fibers (arrows) are demonstrated in Panels C 
(dentate gyrus) and D (hippocampal field CA2). H: hilar region, GL: granule cell layer of dentate gyrus. PL: pyramidal cell 
layer of hippocampus. Bars: 50 p.m. 
tivity is seen in the inferior olivary complex in addition to the 
olivocerebellar tract. A few positive perikarya are also scat- 
tered within the lateral reticular nucleus among the norad- 
renergic perikarya of the A 1 cell group. Many small, positive 
dynorphin-containing perikarya and fibers are distributed in 
the nucleus tractus solitarius and among the noradrenergic 
cell group A2 (Fig. 7A,B). Dynorphin-positive perikarya 
were also noted in the nucleus cuneatus (Fig. 7D), and dif- 
fuse immunoreactivity was seen in the nucleus gracilis. 
Finally, in the spinal cord, a few immunoreactive peri- 
karya were observed in the marginal zone. Dynorphin im- 
munoreactivity was also localized in varicosities scattered 
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FIG. 4. Hypothalamic dynorphin. Panel A shows immunoreactive (dynorphin-17) magnocellular perikarya in the caudal 
supraoptic nucleus (OT: optic tract). At this level, the majority of magnoceUular perikarya are known to be vasopressinergic. 
Panel B is an adjacent section to Panel A demonstrating the complete blockade of immunoreactivity upon pre-adsorption with 
dynorphin-17 (see text). Panel C depicts magnocellular neurons in the posterolateral hypothalamus (FX: fornix), while in Panel 
D, lack of staining is demonstrated in an adjacent section blocked with dynorphin-17 (see text). Bars: 50/zm. 
FACING PAGE: 
FIG. 5. Mesencephalic periaqueductal gray. Panels A, B, and C are photomontaged serial sections through this region stained respectively 
with dynorphin-17, [Leu]enkephalin, and serotonin. Note position of the same capillary lumen (stars) in all three. Dynorphin immunoreactive 
neurons form a group situated ventrally and laterally within the periaqueductal gray (A), whereas [Leu]enkephalin-positive neurons are 
localized more dorsally (B). Note that both dynorphin and [Leu]enkephalin groups are outside the nucleus raphe dorsalis (C). Dashed line in 
Panel C demarcates the separation of dynorphin (Dyn) and enkephalin (Enk) regions. The insets in A and B are high power magnifications of 
each respective neuronal group. Arrows in A and B and their respective magnified areas, point to specific neuronal perikarya. AQ: cerebral 
aqueduct. Bars: 200/zm. Inset bars: 25 p,m. 
947 
• ,'.~'~'~JE~'.-~r~~J~ .. ".~' . " I . r 




















D Y N O R P H I N  IN RA T  C N S  949 
A m p e  
• [ I V  
. ~ 
C • :h '~l D 
r t ~..¢- 
m 
FIG. 7. Dynorphin in the medulla. Panel A shows immunoreactive perikarya (arrows) within the nucleus tractus solitarius (C: central canal). A 
few positively staining neurons of this nucleus are magnified in Panel B. Panel C depicts an immunoreactive neuron (arrow) with four 
processes, within the noradrenergic nucleus A5 (BV: blood vessel). In Panel D, numerous immunoreactive neurons (arrows) are seen in the 
nucleus cuneatus (FC: fasciculus cuneatus). Bars (A, C, D): 50/~m. Bar (B): 25 ~m. 
FACING PAGE: 
FIG. 6. Parabrachial nucleus, locus coeruleus. Panels A, B and C are adjacent sections stained respectively for dynorphin-17 
[Leu]enkephalin, and tyrosine hydroxylase (noradrenergic nucleus locus coeruleus). Insets in A and B are higher magnifications of a specific 
region in each panel. Panel A depicts the position of dynorphin-positive perikarya in the parabrachial nucleus (arrow points to a specific 
neuron magnified in inset). [Leu]enkephalin perikarya (B) form a separate group in this region (arrow points to a specific neuron magnified in 
inset). In Panel C, the position of the locus coeruleus is shown for comparative purposes. Note also the differential location of dynorphin 
(Dyn) and [Leu]enkephalin (Enk) immunoreactive perikarya (around dashed line) in the vicinity of the locus coeruleus and the mesencephalic 
nucleus of the trigeminal nerve (which also contains Dyn), immediately lateral to the locus coeruleus. BC: brachium conjunctivum. V: fourth 
ventricle. Bars: 200 p,m. Inset bars: 10 ptm. 
950 KHACHATURIAN E T  AL .  
throughout the gray matter, but was particularly concen- 
trated in the marginal zone and in immunoreactive patches in 
deeper laminae of  the dorsal horn. 
DISCUSSION 
In the present study, rats given varying doses of col- 
chicine were used to study the distribution of  dynorphin- 
positive neuronal structures in the central nervous system. 
Colchicine acts to inhibit microtubule formation, and 
thereby reduce axonal transport of  material synthesized in 
neurons [12, 16, 38, 52]. The result is accumulation of pep- 
tides and proteins in the perikarya and an enhancement of 
the visual signal obtained by immunocytochemical staining 
of  specific neuronal products. In our experiments, the utili- 
zation of  high doses of colchicine (300-400 ~g/10/~1) has per- 
mitted the localization of peptides and proteins in the small- 
est neuronal elements, including enhanced visualization of 
perikarya, dendrites and axons. In particular, immunoreac- 
tive dynorphin-containing perikarya outside the hypotha- 
lamic magnocellular system are usually not visible with low 
doses of colchicine [78, 85, 86]. For example, Weber et al. 
[86], using lower doses of  colchicine, were able to localize 
immunoreactive fibers but not perikarya in a few of  the re- 
gions reported here. Although direct intracerebral injection 
of  colchicine has been reported to induce neuronal damage 
[21], we have not detected evidence of neuronal damage in 
Nissl-stained sections obtained from animals receiving intra- 
ventricular colchicine injections. The large dose of col- 
chicine used in some animals in these studies has resulted in 
improved visualization of dynorphin cell groups and there- 
fore represents a substantial technical improvement. We are 
unsure of the precise chemical nature and size of  the im- 
munoreactivity in these tissues, but biochemical studies are 
in progress to address these issues. Other immunocytochem- 
ical studies in our laboratory are under way using untreated 
rats and rats with doses of colchicine ranging up to 400/xg, 
with antibodies against dynorphin-17, dynorphin-B, and 
a-neo-endorphin. These studies show that the structures de- 
scribed in the present paper are indeed immunoreactive 
against all three pro-dynorphin produced peptides. Thus, the 
immunoreactivities present in these structures are most 
likely pro-dynorphin products. 
Using antisera generated against various segments 
of the dynorphin molecule, we have localized dynor- 
phin-immunoreactivity in a large number of brain areas 
and the spinal cord. Dynorphin-positive perikarya, fibers 
and terminals were found in the entorhinal cortex, central 
nucleus of  amygdala, hippocampal dentate gyrus, hypotha- 
lamic magnocellular nuclei, mesencephalic periaqueductal 
gray, parabrachial nuclei, brain stem reticular formation, 
several monoaminergic nuclei, nucleus of the spinal tract of 
trigeminal nerve, nucleus tractus solitarius, nucleus cuneatus, 
and spinal cord. In addition, immunoreactive dynorphin fi- 
bers or terminals were localized to the cerebral cortex, olfac- 
tory bulb glomeruli, nucleus accumbens, caudate-putamen, 
globus pallidus, hippocampal mossy fibers, preoptic area, 
hypothalamus, substantia nigra pars reticulata, nucleus locus 
coeruleus, the trigeminal sensory nuclei, motor facial nu- 
cleus, nucleus raphe magnus, certain vestibular and cochlear 
nuclei, reticular formation and spinal gray matter, especially 
the marginal layer and the deeper laminae of the dorsal horn. 
Dynorphin-like immunoreactivlty can be distinguished 
from [Leu]enkephalin immunoreactivity in the brain. Since the 
[Leu]enkephalin sequence (Tyr-Gly-Gly-Phe-Leu) is incorpo- 
rated into the dynorphin peptide (at its NH2-terminus), the 
problem of cross-reactivity of antisera generated against either 
peptide cannot be ignored. To address this problem, we tested 
antisera against several fragments and the full sequence of the 
dynorphin molecule (i.e., 1-13, 7-17, 1-17). The results ob- 
tained using these antisera contrast with the immunocytochem- 
ical staining with anti-[Leu]enkephalin sera as well as antisera 
to an adrenal medullary pro-enkephalin fragment, BAM-22P 
[46]. Using serial section analysis and cross-blocking controls, 
dynorphin immunoreactivity was shown to be present in sys- 
tems which are separate from, but often parallel to those con- 
taining enkephalin immunoreactivity [84]. As an example of a 
non-parallel system, the hypothalamic magnocellular nuclei 
including the supraoptic and paraventricular, all contain 
dynorphin-positive perikarya but not enkephalin-positive 
perikarya [77,78]. In the rat hypothalamus, we have ob- 
served perikaryal enkephalin immunoreactivity only within 
parvocellular neurons. However, immunoreactive magnocel- 
lular enkephalin perikarya have been reported in the rat [61] 
and cat [45] hypothalamus. It should be noted that dynorphin 
had not been sequenced at the time of these studies and was 
not eliminated as the source of immunoreactivity in the mag- 
nocellular neurons. Although [Leu]enkephalin could be 
present in magnocellular neurons as a result of  processing of 
dynorphin, we did not observe enkephalin-like immunoreac- 
tivity in these neurons in the present study. An example of 
separate but adjacent dynorphin and enkephalin systems is 
found in the periaqueductal gray where dynorphin-positive 
perikarya occupy a more ventral position, lateral to the nu- 
cleus raphe dorsalis, whereas immunoreactive 
[Leu]enkephalin perikarya are situated somewhat more dor- 
sally in the periaqueductal gray. Thus, dynorphin-like and 
enkephalin-like immunoreactivity are often present in the 
same brain region, although they are localized in different 
neuronal systems [84]. 
In the olfactory bulb, punctate dynorphin immunoreac- 
tivity was localized in some but not all glomeruli. Further- 
more, this immunoreactivity might originate from the olfac- 
tory nerve. In contrast, immunoreactive [Leu]-enkephalin 
is found in most glomeruli of  the bulb (Khachaturian et al. ,  
J. Neurosci . ,  in press). However, the origin of the opioid 
peptidergic innervation of the olfactory bulb glomeruli requires 
further study. In other telencephalic structures, dynorphin- 
containing and enkephalin-containing systems have been 
difficult to differentiate. These structures include the nucleus 
accumbens, caudate-putamen, globus pallidus, as well as the 
central nucleus of the amygdala, hippocampus and 
entorhinal cortex. In the central nucleus of amygdala, only a 
few scattered perikarya are dynorphin-positive whereas 
considerably more [Leu]enkephalin perikarya can be de- 
tected. In the lateral entorhinal cortex, a few scattered 
dynorphin-positive perikarya can be seen in layer II. Some 
layer II cells are known to project via the perforant path to 
the stratum moleculare of the dentate gyrus [28,67]. So far, 
we have observed very few dynorphin-like immunoreactive 
fibers within the perforant path. In contrast, a distinct 
[Leu]enkephalinergic system exists in the lateral entorhinal 
cortex which appears to project via the perforant path to the 
dentate gyrus ([20] Khachaturian et al., J. Neurosci. ,  in press). 
Within the dentate gyrus, dense immunoreactivity can be seen 
in the mossy fiber system, which constitutes the projection of 
the granule cells to hippocampal fields CA3 and CA2 [4,68]. A 
few faint dynorphin-positive perikarya are present in the 
stratum granulosum which are presumably the source of 
mossy fiber immunoreactivity. Enkephalin-like im- 
munoreactivity has also been demonstrated in the mossy 
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fiber system ([20] Khachaturian et al., J. Neurosci., in 
press). 
In the mesencephalon, substantia nigra exhibits diffuse 
dynorphin-positive immunoreactivity in the pars reticulata, 
whereas the main distribution of enkephalin appears to be in 
the form of punctate varicosities distributed dorsally in the 
pars compacta among dopaminergic neurons. Other 
monoamine-containing nuclei containing dynorphin-like im- 
munoreactivity include the locus coeruleus, raphe dorsalis, 
raphe magnus, and the AI, A2 and A5 noradrenergic cell 
groups of  Dahlstrom and Fuxe [13]. The A2 cell group is 
localized within the nucleus tractus solitarius and dorsal 
motor nucleus of  the vagus nerve. Many small immunoreac- 
tive dynorphin perikarya are also seen in this region as are 
[Leu]enkephalin-positive perikarya. Neither the projections 
of these dynorphin-containing ceils, nor their relationship to 
those containing enkephalin or norepinephrine is clear at 
present. 
In other brain stem regions examined, dynorphin-positive 
fibers were noted in the mesencephalic, main, and spinal 
sensory nuclei of  the trigeminal nerve. The nucleus of  the 
spinal tract of  the trigeminal nerve and nucleus cuneatus also 
contain dynorphin-positive perikarya. Moreover, some of 
the vestibular nuclei and the motor nucleus of the facial 
nerve contain immunoreactive dynorphin fibers. In the 
parabrachial nuclei, dynorphin-positive perikarya were 
noted to form a separate group distinct from that containing 
[Leu]enkephalin-positive perikarya. 
Lastly, in the spinal cord, both perikaryal and diffuse 
immunoreactivity were seen in the marginal zone. In addi- 
tion, distinct patches of dynorphin immunoreactive var- 
icosities were noted in the deeper laminae of  the dorsal horn 
as well as scattered fibers throughout the gray matter. 
[Leu]enkephalin fiber immunoreactivity is prominent in the 
marginal zone of the dorsal horn and is also localized to 
intrinsic spinal interneurons. At present the distinction be- 
tween dynorphin and [Leu]enkephalin immunoreactivities in 
the spinal cord is not clear. 
The widespread distribution of dynorphin-immunoreac- 
tive perikarya and fibers in brain indicates that this opioid 
peptide might have a role in diverse physiological functions. 
Unfortunately, in vivo studies of dynorphin are complicated 
by its marked sensitivity to enzymatic degradation [24, 27, 88]. 
Nevertheless, our anatomical results indicate that several 
possible physiological roles of dynorphin in brain should be 
considered. For example, the colocalization of dynorphin and 
vasopressin in the same hypothalamic magnocellular neurons 
[77] may indicate a coordinate role for these peptides, analo- 
gous to that proposed for other multi-neurotransmitter systems 
(cf. [1]). 
The results of  the present study suggest that sensory 
functions might be influenced by dynorphin at several levels 
of  the central nervous system. The presence of im- 
munoreactive dynorphin perikarya and fibers in the 
periaqueductal gray and fibers in nucleus raphe magnus may 
indicate a role in nociception [2,3]. While in vivo microinjec- 
tion of dynorphin-(1-13) into the periaqueductal gray or cer- 
ebral ventricles did not induce analgesia as measured by the 
tail-flick and vocalization threshold tests [ 19, 73, 88], another 
study using a different measure of pain sensitivity did obtain 
an analgesic effect [54]. The presence of  immunoreactive 
perikarya and processes in the dorsal horn of the spinal cord 
is consistent with a possible role in nociception [8,14]. More 
specifically, the observation of immunoreactive patches in 
deeper laminae of the dorsal horn might indicate a possible 
role for dynorphin in influencing those second order 
nociceptive neurons with perikarya localized in deeper 
laminae and with axons that ascend to several contralateral 
reticular areas, including periaqueductal gray. 
At the level of the medulla, dynorphin-positive perikarya 
in the nucleus cuneatus might receive axons projecting 
through the fasciculus cuneatus from the cervical and upper 
thoracic dorsal root ganglia, which convey proprioceptive 
and very specific tactile input. Extending through the pons 
and medulla, dynorphin-immunoreactive perikarya and fi- 
bers in the nucleus of the spinal tract of the trigeminal nerve 
could form part of the circuitry which processes input from 
the vagal, glossopharyngeal and facial nerve fibers in the 
spinal trigeminal tract which itself contains immunoreactive 
fibers. Neurons in this nucleus are exquisitely sensitive to 
tactile input and are involved in pain impulse transmission as 
well [39,40]. The main sensory nucleus of the trigeminal 
nerve, which contains dynorphin-immunoreactive fibers, re- 
ceives tactile and pressure input from the head. The 
mesencephalic nucleus of the trigeminal nerve, which re- 
ceives proprioceptive input relating to mastication, contains 
both immunoreactive perikarya and fibers. The motor nu- 
cleus of the facial nerve contains immunoreactive fibers 
which could arise from dynorphin-positive perikarya seen in 
the nucleus of  the spinal tract of the trigeminal nerve; the 
pathway connecting these nuclei is involved in corneal and 
other trigeminofacial reflexes [70]. Dynorphin could also be 
involved in processing vestibular input since immunoreac- 
tive fibers are present in both the medial and spinal vestibu- 
lar nuclei. The presence of a large number of immunoreac- 
tive perikarya and fibers in nucleus tractus solitarius is par- 
ticularly suggestive of a role for dynorphin in modulating 
visceral reflex mechanisms, particularly the baroreceptor arc 
[53]. It is interesting that many of the ascending projections 
of  nucleus tractus solitarius are to other areas containing 
dynorphin immunoreactivity, including the parabrachial nu- 
clei [37,51], the paraventricular and arcuate nuclei of hypo- 
thalamus, the central nucleus of the amygdala and the medial 
preoptic area [57]. Exteroceptive sensory processing areas 
containing dynorphin-immunoreactive fibers include the 
superior and inferior colliculi and some glomeruli of the ol- 
factory bulb. 
Dynorphin may also be involved in the regulation of 
motor activity, as indicated by the presence of immunoreac- 
tive fibers and terminals in nucleus caudate-putamen, giobus 
pallidus, nucleus accumbens and the pars reticulata of sub- 
stantia nigra. Other possible loci of motor regulation include 
the inferior olivary complex and olivocerebellar tract which 
contained diffuse immunoreactivity; however, no im- 
munoreactive fibers could be observed in cerebellum al- 
though it contains immunoassayable levels of dynorphin 
[23]. In support of a role in motor activity, intracerebroven- 
tricular administration of dynorphin-(1-13) in mice results in 
both eating and grooming behavior [73]. 
Our anatomical observations have demonstrated the 
separateness ofdynorphin from other opioid peptide systems 
in brain, confirming studies indicating their separate 
biosynthetic origins [I 1, 26, 36, 43, 48, 50, 58]. Nevertheless, 
dynorphin and enkephalin immunoreactivity frequently ap- 
pear in spatially contiguous positions, raising the question of 
how the "messages" of these peptides are differentiated 
postsynaptically. A number of studies using in vitro bioas- 
says and radioreceptor assays have demonstrated the exist- 
ence of multiple subtypes of opiate receptors [9, 25, 41, 42, 
59, 63, 65]. Morphine, D[AIa] 2, D[Leup-enkephalin and 
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e thy lke tocyc l azoc ine  are  cons ide red  to be  p ro to type  l igands 
for  the  mu,  de l ta  and  kappa  opia te  r ecep to r  sub types ,  re- 
spec t ive ly .  In vi tro s tudies  have  s h o w n  tha t  d y n o r p h i n  has  a 
h igher  affinity for  k a p p a  than  o the r  opia te  r ecep to r  sub types ,  
wi th  the  magn i tude  of  d i f ference  depend ing  upon  the t issue 
p repa ra t ion  and  incuba t ion  cond i t ions  [10, 33, 56, 87]. In 
con t ras t ,  the  enkepha l in s ,  par t icular ly  [Leu]enkepha l in ,  ex- 
hibi t  a h igher  affinity for  the  de l ta  opia te  r ecep to r  sub type  
[42]. Thus ,  d y n o r p h i n  and  e n k e p h a l i n  can  be d i sc r imina ted  
at  the  r ecep to r  level ,  a l though  different ia l  pos t r ecep to r  
even t s  el ici ted by  these  in te rac t ions  r emain  to be charac-  
ter ized.  These  cons ide ra t i ons  indicate  tha t  the poten t ia l i ty  of  
enzyma t i c  c o n v e r s i o n  o f  some d y n o r p h i n  to [Leu ]enkepha l in  
r ep re sen t s  a means  by  which  d y n o r p h i n  neu rons  could  
change  the " a d d r e s s "  of  the  opioid " m e s s a g e , "  t r ansmi t t ing  
vary ing  p ropor t ions  of  kappa-d i rec ted  and  de l ta -d i rec ted  
opioids  to the  r ecep to r  si tes in the synapse .  Accord ing ly ,  we 
are a t t empt ing  to de t e rmine  w h e t h e r  enkepha l in  im- 
munoreac t i v i t y  is p re sen t  in a subse t  of  d y n o r p h i n  neu rons  
in brain.  
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